Moisés Manuel Gallardo-Pérez

Dr. Moisés Manuel Gallardo-Pérez

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2025 in Sclerosis
Verified
Journal Article
Open access
PDF file
MGMoisés Manuel Gallardo-Pérez
Moisés Manuel Gallardo-Pérez
ARAlejandro Ruiz-Argüelles
Alejandro Ruiz-Argüelles
GRGuillermo José Ruiz-Argüelles
Guillermo José Ruiz-Argüelles
VRVirginia Reyes-Núñez
Virginia Reyes-Núñez
SSSilvia Soto-Olvera
Silvia Soto-Olvera
SESolón Javier Garcés Eisele
Solón Javier Garcés Eisele
Introduction: Approximately 80% of individuals with multiple sclerosis (MS) have a positive response to autologous hematopoietic stem cell transplantation (aHSCT). Markers that may predict the transplant outcome are necessary. The objective of this work is to identify markers that may refine the selection of patients with multiple sclerosis who could benefit from aHSCT. Methods: We evaluated the levels of six biomarkers in the peripheral blood of patients with MS before aHSCT. The design of this study is cross-sectional; patients were divided into two transplant-responses-at-12-months groups, responders (ΔEDSS < 0) and non-responders (ΔEDSS > 0). Pre-transplant samples were used to assess the different markers. Results: Thirty-four patients were enrolled: fourteen were non-responders and twenty were responders to aHSCT. Among the evaluated biomarkers, a significant difference was only detected in miR-146a levels, with increased values in the non-responder group. Conclusions: The biomarker miR146a could be useful to evaluate the response to aHSCT in patients with MS.